Novo Nordisk Earnings Estimate
| NVO Stock | USD 77.15 1.26 1.66% |
Novo |
Novo Nordisk Earnings Estimation Breakdown
The calculation of Novo Nordisk's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Novo Nordisk is estimated to be 6.2605 with the future projection ranging from a low of 6.06 to a high of 6.461. Please be aware that this consensus of annual earnings estimates for Novo Nordisk AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
6.06 Lowest | Expected EPS | 6.46 Highest |
Novo Nordisk Earnings Projection Consensus
Suppose the current estimates of Novo Nordisk's value are higher than the current market price of the Novo Nordisk stock. In this case, investors may conclude that Novo Nordisk is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Novo Nordisk's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 11 | 94.83% | 6.34 | 6.2605 | 3.3 |
Novo Nordisk Earnings History
Earnings estimate consensus by Novo Nordisk AS analysts from Wall Street is used by the market to judge Novo Nordisk's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Novo Nordisk's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Novo Nordisk Quarterly Gross Profit |
|
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Novo Nordisk's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Novo Nordisk Earnings per Share Projection vs Actual
Actual Earning per Share of Novo Nordisk refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Novo Nordisk AS predict the company's earnings will be in the future. The higher the earnings per share of Novo Nordisk, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Novo Nordisk Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Novo Nordisk, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Novo Nordisk should always be considered in relation to other companies to make a more educated investment decision.Novo Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Novo Nordisk's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-05 | 2024-12-31 | 6.115 | 6.34 | 0.225 | 3 | ||
2024-11-06 | 2024-09-30 | 0.88 | 0.9 | 0.02 | 2 | ||
2024-08-07 | 2024-06-30 | 0.7366 | 0.66 | -0.0766 | 10 | ||
2024-05-02 | 2024-03-31 | 0.77 | 0.83 | 0.06 | 7 | ||
2024-01-31 | 2023-12-31 | 0.66 | 0.71 | 0.05 | 7 | ||
2023-11-02 | 2023-09-30 | 0.69 | 0.73 | 0.04 | 5 | ||
2023-08-10 | 2023-06-30 | 0.63 | 0.67 | 0.04 | 6 | ||
2023-05-04 | 2023-03-31 | 0.61 | 0.63 | 0.02 | 3 | ||
2023-02-01 | 2022-12-31 | 0.4329 | 0.41 | -0.0229 | 5 | ||
2022-11-02 | 2022-09-30 | 0.4189 | 0.43 | 0.0111 | 2 | ||
2022-08-04 | 2022-06-30 | 0.4099 | 0.42 | 0.0101 | 2 | ||
2022-04-28 | 2022-03-31 | 0.4233 | 0.47 | 0.0467 | 11 | ||
2022-02-02 | 2021-12-31 | 0.3566 | 0.36 | 0.0034 | 0 | ||
2021-11-03 | 2021-09-30 | 0.3884 | 0.42 | 0.0316 | 8 | ||
2021-08-04 | 2021-06-30 | 0.3912 | 0.419 | 0.0278 | 7 | ||
2021-05-05 | 2021-03-31 | 0.4035 | 0.44 | 0.0365 | 9 | ||
2021-02-03 | 2020-12-31 | 0.3243 | 0.3239 | -4.0E-4 | 0 | ||
2020-11-03 | 2020-09-30 | 0.3151 | 0.345 | 0.0299 | 9 | ||
2020-08-07 | 2020-06-30 | 0.36 | 0.3593 | -7.0E-4 | 0 | ||
2020-05-05 | 2020-03-31 | 0.345 | 0.3655 | 0.0205 | 5 | ||
2020-02-05 | 2019-12-31 | 0.28 | 0.2724 | -0.0076 | 2 | ||
2019-11-01 | 2019-09-30 | 0.305 | 0.3207 | 0.0157 | 5 | ||
2019-08-09 | 2019-06-30 | 0.3 | 0.3025 | 0.0025 | 0 | ||
2019-05-03 | 2019-03-31 | 0.305 | 0.3267 | 0.0217 | 7 | ||
2019-02-01 | 2018-12-31 | 0.27 | 0.27 | 0.0 | 0 | ||
2018-11-01 | 2018-09-30 | 0.285 | 0.2857 | 7.0E-4 | 0 | ||
2018-08-10 | 2018-06-30 | 0.325 | 0.3267 | 0.0017 | 0 | ||
2018-05-02 | 2018-03-31 | 0.335 | 0.355 | 0.02 | 5 | ||
2018-02-01 | 2017-12-31 | 0.29 | 0.2815 | -0.0085 | 2 | ||
2017-10-27 | 2017-09-30 | 0.305 | 0.315 | 0.01 | 3 | ||
2017-08-09 | 2017-06-30 | 0.3 | 0.3165 | 0.0165 | 5 | ||
2017-05-03 | 2017-03-31 | 0.265 | 0.2979 | 0.0329 | 12 | ||
2017-02-06 | 2016-12-31 | 0.25 | 0.2468 | -0.0032 | 1 | ||
2016-10-28 | 2016-09-30 | 0.28 | 0.2844 | 0.0044 | 1 | ||
2016-08-05 | 2016-06-30 | 1.87 | 0.295 | -1.575 | 84 | ||
2016-04-29 | 2016-03-31 | 1.815 | 0.275 | -1.54 | 84 | ||
2016-02-03 | 2015-12-31 | 1.61 | 0.24 | -1.37 | 85 | ||
2015-10-29 | 2015-09-30 | 1.585 | 0.245 | -1.34 | 84 | ||
2014-05-01 | 2014-03-31 | 0.44 | 0.45 | 0.01 | 2 | ||
2012-04-30 | 2012-03-31 | 0.3 | 0.29 | -0.01 | 3 | ||
2012-02-02 | 2011-12-31 | 0.26 | 0.3 | 0.04 | 15 | ||
2011-10-27 | 2011-09-30 | 0.26 | 0.28 | 0.02 | 7 | ||
2011-08-04 | 2011-06-30 | 0.29 | 0.28 | -0.01 | 3 | ||
2011-02-02 | 2010-12-31 | 0.27 | 0.25 | -0.02 | 7 | ||
2010-10-27 | 2010-09-30 | 0.22 | 0.21 | -0.01 | 4 | ||
2006-10-27 | 2006-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2006-08-02 | 2006-06-30 | 0.09 | 0.09 | 0.0 | 0 | ||
1995-03-08 | 1994-12-31 | 0.02 | 0.02 | 0.0 | 0 | ||
1994-12-22 | 1994-09-30 | 0.02 | 0.02 | 0.0 | 0 | ||
1993-05-15 | 1993-03-31 | 0.01 | 0.01 | 0.0 | 0 |
About Novo Nordisk Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Novo Nordisk earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Novo Nordisk estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Novo Nordisk fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | 144.4 B | 151.7 B | |
| Earnings Yield | 0.04 | 0.03 | |
| Price Earnings Ratio | 27.53 | 28.91 | |
| Price Earnings To Growth Ratio | 0.19 | 0.18 |
Pair Trading with Novo Nordisk
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Moving together with Novo Stock
Moving against Novo Stock
| 0.59 | NBY | NovaBay Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.46 | PFE | Pfizer Inc | PairCorr |
| 0.41 | CCLDP | CareCloud Earnings Call This Week | PairCorr |
| 0.34 | SMMT | Summit Therapeutics PLC | PairCorr |
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.292 | Dividend Share 11.4 | Earnings Share 3.3 | Revenue Per Share | Quarterly Revenue Growth 0.301 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.